The view of Noubar Afeyan, the managing partner of Flagship Ventures, is that the biotech industry, which has always been a bit like an open-air market bazaar, needs to become a little more stable, more predictable. It ought to be part of something you could call an “innovation supply chain.”

Embedded Link

A Biotech Innovation Supply Chain: Reality or Fantasy? | Xconomy
Biotech has always been a bit like an open-air market bazaar. Now the industry needs to become a little more stable, more predictable. It ought to be part

Google+: View post on Google+

Tags:

Comments are closed.